Pharming Group Nv Stock Performance
| PHGUF Stock | USD 0.93 0.05 5.68% |
On a scale of 0 to 100, Pharming Group holds a performance score of 11. The company holds a Beta of -0.0292, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Pharming Group are expected to decrease at a much lower rate. During the bear market, Pharming Group is likely to outperform the market. Please check Pharming Group's variance and the relationship between the treynor ratio and period momentum indicator , to make a quick decision on whether Pharming Group's historical price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Pharming Group NV are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Pharming Group reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 167.1 M | |
| Total Cashflows From Investing Activities | -21.3 M |
Pharming |
Pharming Group Relative Risk vs. Return Landscape
If you would invest 75.00 in Pharming Group NV on December 2, 2024 and sell it today you would earn a total of 18.00 from holding Pharming Group NV or generate 24.0% return on investment over 90 days. Pharming Group NV is currently producing 0.3769% returns and takes up 2.4851% volatility of returns over 90 trading days. Put another way, 22% of traded pink sheets are less volatile than Pharming, and 93% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Pharming Group Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharming Group's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Pharming Group NV, and traders can use it to determine the average amount a Pharming Group's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1517
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PHGUF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.49 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.38 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Pharming Group is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharming Group by adding it to a well-diversified portfolio.
Pharming Group Fundamentals Growth
Pharming Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Pharming Group, and Pharming Group fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharming Pink Sheet performance.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0643 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 721.19 M | |||
| Shares Outstanding | 652.41 M | |||
| Price To Earning | 18.97 X | |||
| Price To Book | 3.94 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 167.68 M | |||
| EBITDA | 41.22 M | |||
| Cash And Equivalents | 189.96 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 122.65 M | |||
| Debt To Equity | 0.75 % | |||
| Book Value Per Share | 0.30 X | |||
| Cash Flow From Operations | 37.84 M | |||
| Earnings Per Share | 0.05 X | |||
| Total Asset | 350.55 M | |||
| Retained Earnings | (273 M) | |||
| Current Asset | 41 M | |||
| Current Liabilities | 18 M | |||
About Pharming Group Performance
By analyzing Pharming Group's fundamental ratios, stakeholders can gain valuable insights into Pharming Group's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pharming Group has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharming Group has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Grp operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 277 people.Things to note about Pharming Group NV performance evaluation
Checking the ongoing alerts about Pharming Group for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pharming Group NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharming Group NV has some characteristics of a very speculative penny stock |
- Analyzing Pharming Group's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharming Group's stock is overvalued or undervalued compared to its peers.
- Examining Pharming Group's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharming Group's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharming Group's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharming Group's pink sheet. These opinions can provide insight into Pharming Group's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pharming Pink Sheet analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |